Alfonso Gómez de Liaño
@Uro_Oncologist
Followers
441
Following
927
Statuses
388
Joined May 2018
RT @DrChoueiri: 1/ JUST IN: an 8 year #kidneycancer journey now published in @Nature: “A personalized neoantigen vaccine generates anti-tum…
0
206
0
RT @cancer_evolve: PROSTATE: in patients with a BRCA1/2 or PALB2 mutation receiving PARP inhibition for advanced disease, progression was a…
0
12
0
RT @pfizer: We are pleased to announce positive topline event-free survival results from our Phase 3 study in patients with BCG-naïve, high…
0
14
0
RT @DrChoueiri: And NOW, TOP 5 PROSTATE CANCER trials of 2024! 1) The ARANOTE trial shows darolutamide + ADT improves rPFS in mHSPC by 46%…
0
173
0
RT @DrChoueiri: IT IS THIS TIME OF THE YEAR AGAIN! TOP 10 GU Bladder/Kidney Cancer TRIALS FOR 2024 1/ Enfortumab Vedotin (EV) + Pembroliz…
0
242
0
RT @tompowles1: TIGIT & LAG3 targets have been explored ➕➕.Merck has stopped their development, joining other IO disappointments(OX40,IDO,…
0
15
0
RT @jsoriamd: FcγR engagement influences antibody efficacy, toxicity & pharmacokinetics: 1) Effector Functions: Critical for anti-CTLA4 to…
0
14
0
RT @Annals_Oncology: 🆕📰New article in press: Biomarker analyses from the phase 3 randomized CLEAR trial: Lenvatinib plus pembrolizumab ver…
0
16
0
RT @tompowles1: CHMP supports belzutifan in advanced clear cell RCC following two or more lines of therapy that included a PD-(L)1 inhibito…
0
19
0
RT @Uromigos: ⭐ Our latest episode with @DrRosenbergMSK focuses on the phase 3 TROPiCS-04 study, which was recently presented at ESMO Asia…
0
11
0
RT @DrChoueiri: Efficacy of Treatments After Lenvatinib in Patients with Advanced Renal Cell Carcinoma - @EurUrolFocus #IMDC stuff fr…
0
6
0
RT @quimmateo: Our review on the current state of PARPi development for #prostatecancer is now out in @EurUrolOncol - led by @FrancescaZacc…
0
19
0
RT @tompowles1: While EVP is better than platinum based chemotherapy in advanced bladder cancer, the debate whether cisplatin is much bette…
0
47
0
RT @GuardConsortium: El Mentorship Research Group de @GuardConsortium lanza el Programa de Mentorización para jóvenes investigadores. Es tu…
0
4
0
RT @desafionco: 🔍 ¿Cómo elegir el mejor doblete terapéutico en cáncer de próstata hormonosensible metastásico? El Dr. Alfonso Gómez de Lia…
0
1
0
RT @DrFelixGuerrero: 🤯¿Eres un joven investigador con un proyecto urooncológico en mente? 🙌🏼¡Eres un potencial crack! 🔬Compártelo con nosot…
0
19
0
RT @GuardConsortium: El Mentorship Research Group de @GuardConsortium lanza el Programa de Mentorización para jóvenes investigadores. Es tu…
0
9
0
RT @RashadNawfal: 1) Excited to share our work @TheLancetOncol on the landscape of subsequent therapies in perioperative IO trials across c…
0
16
0
RT @EurUrolOncol: Penile Cancers Attributed to Human Papillomavirus Are Associated with Improved Survival for Node-positive Patients. Findi…
0
7
0
RT @jsoriamd: ADCs represent one of the most rapidly expanding treatment modalities in oncology, with 11 ADCs FDA-approved & more than 210…
0
41
0